scholarly journals Spinal Cord Injury due to Epidural Puncture in a Patient with Spina Bifida Occulta

2006 ◽  
Vol 26 (7) ◽  
pp. 698-702 ◽  
Author(s):  
Yutaka YAMAZAKI ◽  
Atsushi SAITO ◽  
Hiromu TAKAHASHI
2013 ◽  
pp. 419-458
Author(s):  
KRISTIN J. KROSSCHELL ◽  
MARI JO PESAVENTO

BMJ ◽  
1989 ◽  
Vol 299 (6714) ◽  
pp. 1506-1506 ◽  
Author(s):  
G. S. Muralikrishna ◽  
R. S. Rodger ◽  
A. I. Macdougall ◽  
J. M. Boulton-Jones ◽  
M. E. Allison ◽  
...  

Spinal Cord ◽  
2004 ◽  
Vol 42 (5) ◽  
pp. 308-312 ◽  
Author(s):  
S Vaidyanathan ◽  
P L Hughes ◽  
P Mansour ◽  
B M Soni ◽  
Gurpreet Singh ◽  
...  

BMJ ◽  
1990 ◽  
Vol 300 (6720) ◽  
pp. 331-332 ◽  
Author(s):  
J L Forsythe ◽  
M G Coulthard ◽  
R M Taylor ◽  
R E Lee

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 2837
Author(s):  
Edwin S Kulubya ◽  
Kaitlin Clark ◽  
Dake Hao ◽  
Sabrina Lazar ◽  
Arash Ghaffari-Rafi ◽  
...  

Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.


Author(s):  
Jenny Stevens ◽  
Luis de La Torre ◽  
Jennifer Hall ◽  
Hope Simmons ◽  
Amy Krause ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document